Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biotime Inc (BTX)

Biotime Inc (BTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 137,657
  • Shares Outstanding, K 149,643
  • Annual Sales, $ 4,990 K
  • Annual Income, $ -45,990 K
  • 60-Month Beta 2.77
  • Price/Sales 29.70
  • Price/Cash Flow N/A
  • Price/Book 0.85
  • Price/Earnings ttm 9.90
  • Earnings Per Share ttm 0.10
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/08/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.080 on 12/15/03
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.06
  • Number of Estimates 4
  • High Estimate -0.03
  • Low Estimate -0.09
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.90 +2.21%
on 08/09/19
1.26 -26.99%
on 07/26/19
-0.23 (-20.01%)
since 07/09/19
3-Month
0.90 +2.21%
on 08/09/19
1.28 -28.13%
on 05/10/19
-0.26 (-22.04%)
since 05/09/19
52-Week
0.66 +39.38%
on 12/21/18
2.81 -67.26%
on 09/05/18
-1.39 (-60.18%)
since 08/09/18

Most Recent Stories

More News
BioTime Reports Second Quarter 2019 Financial Results and Provides Business Update

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, reported financial and operating results for the second...

BTX : 0.92 (-7.08%)
BioTime to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that it will report its second quarter 2019...

BTX : 0.92 (-7.08%)
BioTime Announces Name Change to Lineage Cell Therapeutics

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced it is launching a new corporate brand, including...

BTX : 0.92 (-7.08%)
BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has dosed its first patient with the Orbit...

BTX : 0.92 (-7.08%)
Biotime Inc Set to Possibly Rebound After Yesterday's Selloff of 4.39%

Biotime Inc (AMEX:BTX) traded in a range yesterday that spanned from a low of $1.04 to a high of $1.10. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $1.12 on volume...

BTX : 0.92 (-7.08%)
Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1

Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.

ALXN : 113.89 (+6.02%)
BTX : 0.92 (-7.08%)
ACHN : 6.17 (+0.33%)
ANIK : 57.48 (+0.75%)
BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen(R)

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant...

BTX : 0.92 (-7.08%)
BioTime (BTX) Tops Q1 Earnings and Revenue Estimates

BioTime (BTX) delivered earnings and revenue surprises of 600.00% and 40.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

BTX : 0.92 (-7.08%)
BioTime Reports First Quarter 2019 Financial Results and Provides Business Update

--Announced Issuance of New Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury

BTX : 0.92 (-7.08%)
BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced today the issuance of a Notice of Allowance...

BTX : 0.92 (-7.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade BTX with:

Business Summary

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body....

See More

Key Turning Points

2nd Resistance Point 1.00
1st Resistance Point 0.96
Last Price 0.92
1st Support Level 0.89
2nd Support Level 0.86

See More

52-Week High 2.81
Fibonacci 61.8% 1.99
Fibonacci 50% 1.74
Fibonacci 38.2% 1.48
Last Price 0.92
52-Week Low 0.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar